Juvenile Dermatomyositis

临床试验

计划入组 22 人 · 首次发布于 2018 年 2 月 14 日

已完成

NCT05509140

Clinical Analysis of Juvenile Dermatomyositis Patients

计划入组 12 人 · 首次发布于 2022 年 8 月 19 日

Unknown

NCT03432455

Incidence and Prevalence of Juvenile Dermatomyositis

计划入组 22 人 · 首次发布于 2018 年 2 月 14 日

药物

查看全部 11 →

anti-CD19 CAR T-cell therapy (juvenile dermatomyositis)

Allogenic juvenile chondrocytes (Isto Biologics)

Small Molecule

Approved

Oxaprozin(Coxanto, Daypro)

生产企业：Gd searle llc, Actavis elizabeth llc，另有 9 家

相关疾病：Osteoarthritis (OA), Rheumatoid Arthritis，另有 1 项

C₁₈H₁₅NO₃

机构

FONDATION LENVAL NICE

France

CENTRE HOSPITALIER INTERCOMMUNAL DE POISSY SAINT GERMAIN

France

CENTRE HOSPITALIER ANNECY GENEVOIS

France

资讯

查看全部 157 →

2年前

FDA Grants Rare Pediatric Disease Designation to Cartesian's Descartes-08 for Juvenile Dermatomyositis

去年

Cartesian Therapeutics Advances mRNA Cell Therapies for Autoimmune Diseases

8个月前

临床试验

Juvenile Dermatomyositis

Clinical Analysis of Juvenile Dermatomyositis Patients

Incidence and Prevalence of Juvenile Dermatomyositis

药物

anti-CD19 CAR T-cell therapy (juvenile dermatomyositis)

Allogenic juvenile chondrocytes (Isto Biologics)

Oxaprozin(Coxanto, Daypro)

机构

FONDATION LENVAL NICE

CENTRE HOSPITALIER INTERCOMMUNAL DE POISSY SAINT GERMAIN

CENTRE HOSPITALIER ANNECY GENEVOIS

资讯

FDA Grants Rare Pediatric Disease Designation to Cartesian's Descartes-08 for Juvenile Dermatomyositis

Cartesian Therapeutics Advances mRNA Cell Therapies for Autoimmune Diseases

Cartesian Therapeutics Advances CAR-T Therapy Pipeline with FDA Approval for Myositis Trial and Positive Phase 3 Progress